Vanguard Group Inc. Grows Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Vanguard Group Inc. lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,943,895 shares of the biopharmaceutical company’s stock after buying an additional 287,064 shares during the period. Vanguard Group Inc. owned approximately 0.09% of Alnylam Pharmaceuticals worth $2,286,181,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Quent Capital LLC increased its holdings in Alnylam Pharmaceuticals by 246.0% during the 4th quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares during the period. Anchor Investment Management LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $38,000. Robeco Institutional Asset Management B.V. increased its holdings in Alnylam Pharmaceuticals by 155.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 12,513 shares during the period. GAMMA Investing LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $52,000. Finally, V Square Quantitative Management LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $52,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 1.9 %

Shares of ALNY opened at $157.30 on Tuesday. The firm has a market cap of $19.90 billion, a PE ratio of -58.69 and a beta of 0.30. The firm has a fifty day simple moving average of $150.05 and a two-hundred day simple moving average of $162.68. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.23. The company had revenue of $494.33 million for the quarter, compared to analysts’ expectations of $428.01 million. Alnylam Pharmaceuticals’s quarterly revenue was up 54.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.40) earnings per share. As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -3.77 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ALNY. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $165.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. Chardan Capital reaffirmed a “buy” rating and set a $225.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, May 3rd. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, April 8th. StockNews.com raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 29th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $235.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. Seven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $216.19.

Insider Transactions at Alnylam Pharmaceuticals

In other news, Director Amy W. Schulman sold 21,700 shares of the company’s stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total value of $3,224,620.00. Following the completion of the sale, the director now directly owns 8,436 shares in the company, valued at approximately $1,253,589.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.